The Study
Prognostic and therapeutic potential of copper-induced cell death-related lncRNAs in lung squamous cell carcinoma
This study looked at existing data from cancer patients to find patterns between certain genes and how long they lived. It found that some gene patterns were linked to shorter survival or better drug responses, but it didn't test if changing those genes actually caused the changes.
Analysis score
Maximum 0 for a computational/algorithm study.
Where the score came from
Scientists found five special RNA molecules in lung cancer cells that, when measured together, can tell if a patient is likely to live longer or shorter.
Where does this study sit?
Reviews of RCTs (Meta-analyses)
Max 100Randomized Trials
Max 90Reviews of Cohort Studies
Max 85Cohort Studies
Max 72Reviews of Case-Control Studies
Max 63Case-Control Studies
Max 58Cross-Sectional & Case Series
Max 50Expert Opinion
Max 50 / 100
Quality score
Based on clinical experience or non-systematic literature reviews. The lowest level of evidence as they are most susceptible to bias and personal perspective.
Key takeaways
Summary
Based on the study abstract and findings.
- 1Yes — this means doctors could use this gene score to pick better treatments and warn patients who are at higher risk of dying soon.
- 2High-risk patients lived about 40% less time than low-risk patients.
- 3They were also less likely to respond to immunotherapy but more likely to respond to drugs like Quizartinib and Dasatinib.
Score breakdown, methodology, conflicts of interest, evidence analysis & raw study data
Publication
Journal
Clinical and Experimental Medicine
Year
2025
Authors
Z. Tian, Lilan Cen, Haoming Hua, Feng Wei, Jue Dong, Yulan Huang, Zhibo Wang, Junhua Deng, Yujie Jiang
Related Content
Claims (5)
Patients with lung squamous cell carcinoma classified as high-risk by a specific genetic risk score respond more strongly to the drugs Quizartinib and Dasatinib than low-risk patients, as measured by lower drug concentrations needed to inhibit cancer cell growth.
A mathematical model combining a genetic risk score related to copper-induced cell death with patient age, cancer stage, and gender more accurately predicts survival at 1, 3, and 5 years in lung squamous cell carcinoma than using age, stage, and gender alone.
In patients with high-risk lung squamous cell carcinoma, specific genes involved in breaking down drugs are more active, which is associated with changes in how these patients respond to medications.
In patients with lung squamous cell carcinoma, a specific combination of five RNA molecules predicts shorter survival times; those classified as high-risk live about 40% less time than those classified as low-risk.
In patients with lung squamous cell carcinoma, those identified as high-risk by a specific genetic risk score show stronger signs of immune system suppression and respond less effectively to immunotherapy compared to those classified as low-risk.
Not medical advice. For informational purposes only. Always consult a qualified healthcare professional before making health decisions.